NSE: ZYDUSLIFE | BSE: 532321

Strong Performer, Getting Expensive

Download real time

996.10 5.05 (0.51%)

25.30% Gain from 52W Low

1.1M NSE+BSE Volume

NSE 02 Sep, 2025 3:50 PM (IST)

100,231

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Search Inside the pdf :

Zydus Lifesciences Ltd.

25 Aug 2025

996.10

0.51%

Q1FY26 performance stood stable amid slower traction in US offset by new product launches

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.

Zydus Lifesciences L.. has an average target of 1021.00 from 6 brokers.

Zydus Lifesciences Ltd.

13 Aug 2025

996.10

0.51%

Momentum may fizzle out on loss of exclusivities

Hold: Zydus Lifesciences Ltd.

ICICI Securities Limited

Zydus Lifesciences (Zydus)’s Q1FY26 print beat our expectations, though its revenue grew a mere 5.9% while EBITDA/PAT shrunk 3.3%/0.7% YoY. US biz sales were flat YoY.

Zydus Lifesciences Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

13 Aug 2025

996.10

0.51%

Zydus Lifesciences (ZYDUSLIF IN) Q1FY26 Result Update Higher...

Accumulate: Zydus Lifesciences Ltd.

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q1 EBITDA beat our estimates by 5%. We believe gRevlimid + gMirabegron contributes +45% to total FY25/Q1FY26 EPS which will see erosion from H2FY26. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27 given sales erosion in some of...

Deven Choksey increased Buy price target of Zydus Lifesciences Ltd. to 1183.0 on 25 Aug, 2025.

Zydus Lifesciences Ltd.

25 Jul 2025

996.10

0.51%

Stock Flash

Buy: Zydus Lifesciences Ltd.

Deven Choksey

Zydus Lifesciences Ltd has received tentative approval from the United States Food and Drug Administration (USFDA) for its Ibrutinib tablets in 140 mg, 280 mg, and 420 mg strengths.

Zydus Lifesciences L.. has an average target of 1021.00 from 6 brokers.

Zydus Lifesciences Ltd.

21 May 2025

996.10

0.51%

Zydus Lifesciences (ZYDUSLIF IN) Q4FY25 Result Update High...

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q4 EBITDA including other operating income beat our estimates by 8%. We believe gRevlimid + gMirabegron contributes +45% to total FY25E EPS which will see erosion from FY27. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27...

Deven Choksey increased Buy price target of Zydus Lifesciences Ltd. to 1183.0 on 25 Aug, 2025.

Zydus Lifesciences Ltd.

21 May 2025

996.10

0.51%

Headwinds in US to curtail margins

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) Q4FY25 revenue gained with healthy traction in US (+20%), domestic branded formulation (+10.7%) and its consumer business (+17.1%).

Deven Choksey increased Buy price target of Zydus Lifesciences Ltd. to 1183.0 on 25 Aug, 2025.

Zydus Lifesciences Ltd.

16 Apr 2025

996.10

0.51%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Zydus Lifesciences Ltd. is trading above all available SMAs

Zydus Lifesciences Ltd.

06 Feb 2025

996.10

0.51%